Outcomes of Obese and Morbidly Obese Patients Undergoing Percutaneous Coronary Intervention

被引:6
作者
Paratz, Elizabeth D. [1 ]
Wilkinson, Luke E. [2 ]
MacIsaac, Andrew I. [1 ]
机构
[1] St Vincents Hosp, Dept Cardiol, Melbourne, Vic, Australia
[2] St Vincents Hosp, Dept Med Engn & Phys, Melbourne, Vic, Australia
关键词
Morbid obesity; Percutaneous coronary intervention; Radiation; Monte Carlo; ESTIMATING RENAL-FUNCTION; IN-HOSPITAL OUTCOMES; CARDIAC-CATHETERIZATION; REDUCTION; WEIGHT;
D O I
10.1016/j.hlc.2017.08.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The risks of percutaneous coronary intervention (PCI) in obese and particularly morbidly obese patients remain uncertain. Methods: 1082 consecutive patients were categorised as non-obese (NO, body mass index (BMI) <30kg/m(2), n = 688), obese (O, BMI 30-40kg/m(2), n = 354) or morbidly obese (MO, BMI >= 40kg/m(2), n = 40). Demographic and procedural information was collated. Monte Carlo simulations modelled radiation dosimetric data. Results: Obese and morbidly obese patients were younger (p = 0.016), more frequently female (p = 0.036), more frequently diabetic (p < 0.0001), with better renal function (p < 0.0001), and prior PCI (p = 0.01). There was no difference in major adverse cardiovascular or cerebrovascular events (MACCE) (NO = 1.2%, O = 0.8%, MO = 2.5%, p = NS), acute kidney injury, bleeding, length of stay, 30-day readmission or 30-day mortality. Obese and morbidly obese patients received increased contrast (NO = 180 [150-230]mL, O = 190 [160-250]mL, MO = 200 [165-225]mL, p = 0.016), dose area product (NO = 75.56 [50.61-113.69]Gycm(2), O = 116.4 [76.11-157.82]Gycm(2), MO = 125.62 [92.22-158.81]Gycm(2), p < 0.0001), entrance air kerma (NO = 1439.42 [977.0-2075.5]mGy, O = 2111.63 [1492.0-3011.0]mGy, MO = 2376.0 [1700.0-3234.42]mGy, p < 0.0001), and peak skin dose (NO = 1439.42 [977.0-2075.5], O = 2111.63 [1492.0-3011.0], MO = 2376.0 [1700.0-3234.42], p < 0.0001). Effective radiation dose increased in obese patients (NO = 20.9 +/- 14.9mSv, O = 27.4 +/- 17.1mSv, MO = 24.1 +/- 12.6mSv, p < 0.0001 for NO vs O, p = 0.449 for NO vs MO). Conclusions: Percutaneous coronary intervention can be performed in obese and morbidly obese patients without elevated risk for most clinical outcomes. However, radiation increases above levels that could cause both transient and late effects. Strategies should be pursued to minimise radiation dose.
引用
收藏
页码:785 / 791
页数:7
相关论文
共 50 条
[41]   Transradial access for visceral endovascular interventions in morbidly obese patients: safety and feasibility [J].
Biederman, Derek M. ;
Marinelli, Brett ;
O'Connor, Paul J. ;
Titano, Joseph J. ;
Patel, Rahul S. ;
Kim, Edward ;
Tabori, Nora E. ;
Nowakowski, Francis S. ;
Lookstein, Robert A. ;
Fischman, Aaron M. .
JOURNAL OF VASCULAR ACCESS, 2016, 17 (03) :256-260
[42]   Patients with atrial fibrillation undergoing percutaneous coronary intervention [J].
Dzeshka, Mikhail S. ;
Brown, Richard A. ;
Lip, Gregory Y. H. .
POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2015, 125 (1-2) :73-+
[43]   Efficacy of venous thromboembolism prophylaxis in morbidly obese patients undergoing gastric bypass surgery [J].
Cotter, SA ;
Cantrell, W ;
Fisher, B ;
Shopnick, R .
OBESITY SURGERY, 2005, 15 (09) :1316-1320
[44]   Insulin Resistance Predicts Steatosis and Fibrosis in Morbidly Obese Patients Undergoing Bariatric Surgery [J].
Aller, Rocio ;
de Luis, Daniel ;
Pacheco, David ;
Concepcion Velasco, Maria ;
Izaola, Olatz ;
Gonzalez Sagrado, Manuel .
JOURNAL OF INVESTIGATIVE MEDICINE, 2012, 60 (07) :1005-1008
[45]   Efficacy of Venous Thromboembolism Prophylaxis in Morbidly Obese Patients Undergoing Gastric Bypass Surgery [J].
Samantha Ann Cotter ;
Wendy Cantrell ;
Barry Fisher ;
Rinah Shopnick .
Obesity Surgery, 2005, 15 :1316-1320
[46]   Contrast nephropathy in patients undergoing percutaneous coronary intervention [J].
Gorczyca-Michta, Iwona ;
Wozakowska-Kaplon, Beata .
POSTEPY W KARDIOLOGII INTERWENCYJNEJ, 2011, 7 (02) :165-172
[47]   Quality of Life in Patients Undergoing Percutaneous Coronary Intervention [J].
Tsoulou, Vasiliki ;
Vasilopoulos, Georgios ;
Kapadochos, Theodore ;
Pavlatou, Niki ;
Kalogianni, Antonia ;
Toulia, Georgia ;
Dousis, Evangellos ;
Panoutsopoulos, George ;
Kourakos, Michael ;
Polikandrioti, Maria .
CLINICS AND PRACTICE, 2023, 13 (03) :621-637
[48]   The role of eptifibatide in patients undergoing percutaneous coronary intervention [J].
Zeymer, Uwe .
EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (08) :1147-1154
[49]   Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention [J].
Li, Tianyu ;
Tang, Xiaofang ;
Song, Ying ;
Yao, Yi ;
Zhao, Xueyan ;
Gao, Zhan ;
Yang, Yuejin ;
Gao, Runlin ;
Xu, Bo ;
Yuan, Jinqing .
GLOBAL HEART, 2021, 16 (01)
[50]   Overview of in-hospital outcomes in patients undergoing percutaneous coronary intervention with the revived directional coronary atherectomy [J].
Numasawa, Yohei ;
Inohara, Taku ;
Ishii, Hideki ;
Yamaji, Kyohei ;
Kohsaka, Shun ;
Sawano, Mitsuaki ;
Amano, Tetsuya ;
Nakamura, Masato ;
Ikari, Yuji .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2022, 100 (01) :51-58